摘要 |
Compounds of the formula (I) wherein R represents OH or NHOH; R1 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl, or acyl derived from a carboxylic acid, from a carbonic acid, from a carbamic acid of from a sulfonic acid; R2 represents biarylsulfonyl or aryloxyarylsufonyl; R3 represents hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, cycloalkyl-lower alkyl or acyl derived from a carboxylic acid, from a carbonic acid or form a carbamic acid; R4 and R5 represent independently hydrogen, lower alkyl, lower alkoxycarbonyl, aryl-lower alkyl or cycloalkyl-lower alkyl; m is zero, 1, 2 or 3; pharmaceutically acceptable prodrug derivatives thereof; pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; and their use for inhibiting matrix degrading metalloproteinases and preventing or treating matrix metalloproteinase dependent conditions in mammals. |
申请人 |
NOVARTIS AG;NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.;FUJIMOTO, ROGER, AKI;MCQUIRE, LESLIE, WIGHTON;MONOVICH, LAUREN, G.;NANTERMET, PHILIPPE;PARKER, DAVID, THOMAS;ROBINSON, LESLIE, ANN;SKILES, JERRY, W.;TOMMASI, RUBEN, ALBERTO |
发明人 |
FUJIMOTO, ROGER, AKI;MCQUIRE, LESLIE, WIGHTON;MONOVICH, LAUREN, G.;NANTERMET, PHILIPPE;PARKER, DAVID, THOMAS;ROBINSON, LESLIE, ANN;SKILES, JERRY, W.;TOMMASI, RUBEN, ALBERTO |